Saturday, July 11, 2026

Drug profile · INN

fluphenazine enanthate

fluphenazine enanthate (PROLIXIN ENANTHATE) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — fluphenazine enanthate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

fluphenazine enanthate (PROLIXIN ENANTHATE) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN fluphenazine enanthate
Brand PROLIXIN ENANTHATE
Mechanism Dopamine D2 receptor antagonist
Target D(2) dopamine receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Dopamine D2 receptor antagonist

Primary target: D(2) dopamine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. cabergoline Dopamine D2 receptor agonist
  4. clozapine Serotonin 2a (5-HT2a) receptor antagonist
  5. fluphenazine decanoate Dopamine D2 receptor antagonist
  6. fluphenazine hydrochloride Dopamine D2 receptor antagonist

Frequently asked questions

What is fluphenazine enanthate?

fluphenazine enanthate (PROLIXIN ENANTHATE) is a dopamine d2 receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for fluphenazine enanthate?

PROLIXIN ENANTHATE is a marketed brand name for fluphenazine enanthate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of fluphenazine enanthate?

fluphenazine enanthate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.